2689:HKEXNine Dragons Paper Holdings Ltd. Analysis
Data as of 2026-08-01 - not real-time
¥1,910.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock trades around 1,910 JPY, sitting below its 20‑day (≈1,931) and 50‑day (≈1,978) moving averages, signalling a bearish price environment. The 30‑day volatility of roughly 24% and a decreasing volume trend further underscore short‑term pressure. Yet the price‑to‑earnings multiple of about 9× is dramatically cheaper than the industry average of 29×, and the price‑to‑book is under 1.0, indicating a sizable valuation discount. The dividend yield of 4.2% with a payout ratio near 38% looks attractive, though operating cash flow is currently flat. RSI at 40 hints the stock is not yet deeply oversold, while the MACD histogram turned positive, offering a hint of technical relief. Recent nine‑month results showed revenue growth of 4.6% and a modest net profit, confirming modest top‑line momentum.
However, the absence of operating and free cash flow raises questions about the durability of the dividend, and the debt‑to‑equity of 27% adds balance‑sheet leverage risk. The beta close to zero suggests limited sensitivity to broader market moves, but the sector’s regulatory environment and Japan‑centric operations introduce medium‑level risks. Given the valuation gap and dividend appeal, the stock may be a candidate for a patient buy, provided investors are comfortable with cash‑flow constraints. In the near term, the bearish technical backdrop advises caution, but the medium‑term upside potential remains compelling.
However, the absence of operating and free cash flow raises questions about the durability of the dividend, and the debt‑to‑equity of 27% adds balance‑sheet leverage risk. The beta close to zero suggests limited sensitivity to broader market moves, but the sector’s regulatory environment and Japan‑centric operations introduce medium‑level risks. Given the valuation gap and dividend appeal, the stock may be a candidate for a patient buy, provided investors are comfortable with cash‑flow constraints. In the near term, the bearish technical backdrop advises caution, but the medium‑term upside potential remains compelling.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages
- Decreasing volume and elevated volatility
- Attractive dividend but weak cash‑flow generation
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation discount to peers
- Sustainable dividend yield if cash‑flow improves
- Potential support around 1,871 JPY offering upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Low PE and P/B relative to industry
- Stable healthcare demand in Japan
- Long‑term dividend income despite current cash‑flow concerns
Key Metrics & Analysis
Financial Health
Revenue Growth4.60%
Profit Margin1.09%
P/E Ratio9.2
ROE11.25%
ROA2.50%
Debt/Equity27.20
P/B Ratio0.9
Industry P/E29.2
Technical Analysis
TrendBearish
RSI39.8
Support¥1,871.00
Resistance¥2,020.00
MA 20¥1,930.70
MA 50¥1,977.60
MA 200¥2,053.05
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
GradeUndervalued
TypeValue
Dividend Yield4.19%
Risk Assessment
Beta-0.02
Volatility23.65%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.